These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16468521)

  • 1. Administration of nesiritide in patients after coronary artery bypass surgery induces brisk diuresis.
    Benharash P; Omari B
    Am Surg; 2005 Sep; 71(9):794-6. PubMed ID: 16468521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP).
    Salzberg SP; Filsoufi F; Anyanwu A; von Harbou K; Gass A; Pinney SP; Carpentier A; Adams DH
    Ann Thorac Surg; 2005 Aug; 80(2):502-6. PubMed ID: 16039193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
    Kurien S; Warfield KT; Wood CM; Miller WL
    Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary experience with nesiritide in pediatric patients less than 12 months of age.
    Ryan A; Rosen DA; Tobias JD
    J Intensive Care Med; 2008; 23(5):321-8. PubMed ID: 18603536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects and safety of nesiritide in neonates with heart failure.
    Simsic JM; Mahle WT; Cuadrado A; Kirshbom PM; Maher KO
    J Intensive Care Med; 2008; 23(6):389-95. PubMed ID: 18805856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patients.
    Brackbill ML; Stam MD; Schuller-Williams RV; Dhavle AA
    Ann Pharmacother; 2007 Mar; 41(3):427-32. PubMed ID: 17311834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential renal protective benefits of intra-operative BNP infusion during cardiac transplantation.
    Zierer A; Voeller RK; Melby SJ; Kawa CB; Guthrie TJ; Baumgartner M; Pasque MK; Moon MR; Moazami N
    Transplant Proc; 2006 Dec; 38(10):3680-4. PubMed ID: 17175366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of nesiritide in pediatric heart failure.
    Jefferies JL; Price JF; Denfield SW; Chang AC; Dreyer WJ; McMahon CJ; Grenier MA; Clunie SK; Thomas A; Moffett BS; Wann TS; Smith EO; Towbin JA
    J Card Fail; 2007 Sep; 13(7):541-8. PubMed ID: 17826644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nesiritide for the treatment of decompensated heart failure.
    Colucci WS
    J Card Fail; 2001 Mar; 7(1):92-100. PubMed ID: 11264555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nesiritide as bridge to multi-organ transplantation: a case report.
    Cochrane AB; Fedson SE; Cronin DC
    Transplant Proc; 2007; 39(1):308-10. PubMed ID: 17275531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial.
    Mentzer RM; Oz MC; Sladen RN; Graeve AH; Hebeler RF; Luber JM; Smedira NG;
    J Am Coll Cardiol; 2007 Feb; 49(6):716-26. PubMed ID: 17291938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nesiritide: past, present, and future.
    Burger AJ; Burger MR
    Minerva Cardioangiol; 2005 Dec; 53(6):509-22. PubMed ID: 16333235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary experience with nesiritide in the pediatric population.
    Marshall J; Berkenbosch JW; Russo P; Tobias JD
    J Intensive Care Med; 2004; 19(3):164-70. PubMed ID: 15154997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nesiritide use in pediatric patients with congestive heart failure.
    Feingold B; Law YM
    J Heart Lung Transplant; 2004 Dec; 23(12):1455-9. PubMed ID: 15607680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nesiritide on renal function in patients admitted for decompensated heart failure.
    Arora S; Clarke K; Srinivasan V; Gradman A
    QJM; 2007 Nov; 100(11):699-706. PubMed ID: 17971392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous low-dose human atrial natriuretic peptide promotes diuresis in oliguric patients after living donor liver transplantation.
    Sato K; Sekiguchi S; Kawagishi N; Akamatsu Y; Enomoto Y; Takeda I; Fukushima D; Fujimori K; Sato A; Satomi S
    Transplant Proc; 2006 Dec; 38(10):3591-3. PubMed ID: 17175340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent outpatient nesiritide infusion reduces hospital admissions in patients with advanced heart failure.
    Schwarz ER; Najam S; Akel R; Sulimanjee N; Bionat S; Rosanio S
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):232-6. PubMed ID: 17875951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients.
    Chow SL; Peng JT; Okamoto MP; Heywood JT
    Ann Pharmacother; 2007 Apr; 41(4):556-61. PubMed ID: 17389662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative nesiritide use following high-risk mitral valve replacement.
    Entwistle JW; McLoughlin DE; Baghelai K
    Heart Surg Forum; 2004; 7(3):E189-90. PubMed ID: 15262599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nesiritide therapy in a term neonate with renal disease.
    Moffett BS; Jefferies JL; Rossano J; Towbin JA
    Pharmacotherapy; 2006 Feb; 26(2):281-4. PubMed ID: 16466334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.